FindTrial
Sign In

Construction of individual medication model of posaconazole in patients with hematopathy based on sparse plasma concentration

Construction of individual medication model of posaconazole in patients with hematopathy based on sparse plasma concentration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068601
Enrollment
Unknown
Registered
2023-02-24
Start date
2023-02-25
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant hematopathy

Interventions

Test group:Measure the plasma concentration of posaconazole

Sponsors

Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Age >= 18 years old; Patients with malignant hematopathy; (2) Take posaconazole oral suspension for more than 7 days; (3) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients allergic to posaconazole; (2) Patients who take medicine outside the hospital's order; (3) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Plasma drug concentration of posaconazole;—

Countries

China

Contacts

Public ContactGuoping Yang

Clinical Pharmacology Center, Third Xiangya Hospital, Central South University

ygp9880@163.com13974817168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026